ProteoNic Revenue and Competitors

ProteoNic is a biotechnology company offering products and services for improving recombinant protein production levels for a range of eukaryotic production platforms. This leads to greater manufacturing flexibility, with lower production costs improving economics for antibodies and other biopharmaceutical proteins. The company's proprietary UNicâ„¢ technology is based on improving (the translation of) messenger RNA (mRNA). ProteoNic second generation (2G UNicâ„¢) mammalian expression vectors add new proprietary yield enhancing elements to its existing mRNA elements. The combination of elements in the 2G UNicâ„¢ vectors provides a synergistic enhancement enabling the generation of high yielding stable cell lines. This can also be achieved by implementation of individual UNicâ„¢ elements in existing commercial vectors. UNicâ„¢ is complementary to existing production technologies including improved promotors, vectors and other transcriptional approaches. The 2G UNicâ„¢ technology toolbox products are provided under royalty free license agreement. In addition, ProteoNic offers contract services for expression vector construction and cell line or strain development in support of the implementation of UNicâ„¢ technology. The company is headquartered at the BioScience Park in Leiden, the Netherlands and has a Boston, USA office for Business Development in the North American market. ProteoNic is the winner of the 2010 Frost & Sullivan Technology Innovation Award.